Protocol Ledger

NCT04411082 · Phase II · TERMINATED

A Study of IMR-687 in Subjects With Beta Thalassemia

Interventional Phase II clinical trial protocol NCT04411082 sponsored by Cardurion Pharmaceuticals in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-10-16 Enrollment: 122 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04411082
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)122 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04411082
Protocol FieldVerified Registry Value
NCT IdentifierNCT04411082
Consolidated Lead SponsorCardurion Pharmaceuticals
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment122 participants (ACTUAL)
Registered Start Date2020-10-16
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04411082
Hospital Research SiteLocationSite Profile
Rambam Health Care CampusHaifa, IsraelOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI